Home>>Signaling Pathways>> Microbiology & Virology>> HIV>>DDX3-IN-2

DDX3-IN-2

Catalog No.GC64391

DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC50 value of 0.3 μM.

Products are for research use only. Not for human use. We do not sell to patients.

DDX3-IN-2 Chemical Structure

Cas No.: 1919828-81-1

Size Price Stock Qty
5 mg
$162.00
In stock
10 mg
$270.00
In stock
25 mg
$531.00
In stock
50 mg
$855.00
In stock
100 mg
$1,350.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC50 value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance[1].

DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase[1].

DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg[1].DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values[1].

[1]. Brai A, et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc Natl Acad Sci U S A. 2016;113(19):5388-5393.

Reviews

Review for DDX3-IN-2

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DDX3-IN-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.